SPECT Imaging with Bifunctional Technetium-99m Nitrido Bis(thiosemicarbazonato) Complexes Tethered to Inhibitors of the Prostate-Specific Membrane Antigen
Molecular Pharmaceutics · 06.04.2026 · 23 (4) · 2669-2681
DOI: 10.1021/acs.molpharmaceut.5c01804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 03.03.2026. Verfasst von Rachel C Maclean und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, Monash University, Clayton, VIC 3800, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Technetium, Glutamate Carboxypeptidase II, Radiopharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Australian Cancer Research Foundation, Ian Potter Foundation.
Abstract (Originalsprache)
We report the design and synthesis of new conjugates (H2L1-4) consisting of a bifunctional bis(thiosemicarbazone) chelator conjugated to prostate-specific membrane antigen pharmacophores. Radiolabeling H2L1-4 with the 99mTc nitrido core in a one-pot synthesis at 95 °C for 10 min produced the complexes [99mTc][TcN(L1-4)] with high radiochemical purity (RCP > 95%) and excellent stability. In vitro evaluation of the [99mTc]Tc PSMA complexes demonstrated high cell-surface receptor binding and internalization in cancer cells expressing PSMA (PSMA+), which was inhibited by an excess of a PSMA-specific inhibitor. The most lipophilic of the complexes, [99mTc][TcN(L2)], also showed significant nonspecific uptake in the control cell line (PSMA-). SPECT-CT imaging of the four complexes, at 1 and 4 h postinjection and biodistribution studies at 5 h postinjection in BALB/c nude mice with both PSMA+ and PSMA- tumors, demonstrated significant differences in the receptor-specific tumor uptake and clearance pathways. [99mTc][TcN(L3)] and the bivalent [99mTc][TcN(L4)] showed predominantly renal clearance and the highest PSMA+ tumor uptake and retention. Conversely, [99mTc][TcN(L1)] and [99mTc][TcN(L2)] displayed gastrointestinal clearance and lower PSMA+ tumor uptake. The work demonstrates that bis(thiosemicarbazones) are effective bifunctional chelators for the development of 99mTc radiopharmaceuticals targeting PSMA with the potential to be easily modified to target other diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry, Monash University, Clayton, VIC 3800, Australia.
- Centre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia.
- ARC Centre for Innovation in Biomedical Imaging Technology (CIBIT), The University of Queensland, Brisbane, Queensland 4072, Australia.
- ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR), The University of Queensland, Brisbane, QLD 4072, Australia.
- Monash Biomedical Imaging, Monash University, Clayton, VIC 3800, Australia.
ORCID-Profile: Rachel C Maclean, Nicholas L Fletcher, Kellie L Tuck, Brett M Paterson
Förderung
- Australian Cancer Research Foundation
- Ian Potter Foundation
Zitieren
APA
Maclean, R. C., Fletcher, N. L., Chu, W., Lim, T. X., Tuck, K. L., & Paterson, B. M. (2026). SPECT Imaging with Bifunctional Technetium-99m Nitrido Bis(thiosemicarbazonato) Complexes Tethered to Inhibitors of the Prostate-Specific Membrane Antigen. Molecular Pharmaceutics, 23(4), 2669-2681. https://doi.org/10.1021/acs.molpharmaceut.5c01804
Vancouver
Maclean RC, Fletcher NL, Chu W, Lim TX, Tuck KL, Paterson BM. SPECT Imaging with Bifunctional Technetium-99m Nitrido Bis(thiosemicarbazonato) Complexes Tethered to Inhibitors of the Prostate-Specific Membrane Antigen. Molecular Pharmaceutics. 2026;23(4):2669-2681. doi:10.1021/acs.molpharmaceut.5c01804
BibTeX
@article{Maclean2026,
author = {Maclean, Rachel C and Fletcher, Nicholas L and Chu, Weijing and Lim, Ting Xiang and Tuck, Kellie L and Paterson, Brett M},
title = {SPECT Imaging with Bifunctional Technetium-99m Nitrido Bis(thiosemicarbazonato) Complexes Tethered to Inhibitors of the Prostate-Specific Membrane Antigen},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {4},
pages = {2669--2681},
doi = {10.1021/acs.molpharmaceut.5c01804}
}
EUVIMED